Disclosure : S. Rivella is a consultant for Novartis, Isis and Biomarin Pharmaceuticals. In addition, he is a co-inventor for the patents US8058061 B2 C12N 20111115 and US7541179 B2
C12N 20090602. The consulting work and intellectual property of S. Rivella did not affect in any way the design, conduct, or reporting of this research.
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||


